- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05051930
A Clinical Trial of TQC3721 Suspension for Inhalation
October 22, 2021 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of TQC3721 Suspension for Inhalation
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD)and asthma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
114
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weimin Li, Post Doctor
- Phone Number: 028-85423837
- Email: llllllv2@126.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Weimin Li, Post Doctor
- Phone Number: 028-85423837
- Email: llllllv2@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the test;
- Able to complete the study according to the requirements of protocol;
- Aged between 18 and 65 years old, both men and women;
- For healthy subjects: Male ≥50kg, female ≥45kg,body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value); For patients: BMI is 18-28 kg/m2 (including the critical value), and body weight is ≥45kg.
- For healthy subjects: normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance;
- For healthy subjects: FEV1 and forced vital capacity(FVC) are at least 90% of the predicted values;
- Subjects (including male subjects) have no pregnancy plan and have voluntarily taken effective contraceptive measures for at least 1 month after being screened to the last use of the study drug;
- For patients: Vital signs range: systolic blood pressure 90 to 140mmHg, diastolic blood pressure 50 to 90 mmHg, heart rate 50 to 90 bpm;
- For patients: 12-lead electrocardiogram with QT interval corrected ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no morphologic and other clinical significant abnormalities (such as left band branch block, atrioventricular node dysfunction, ischemic ST segment abnormalities);
- For patients: Ability to perform acceptable and reproducible spirometry;
- For patients: According to the diagnostic criteria of 2018 Practical Edition of Guidelines for the Diagnosis and Treatment of COPD, the patient was diagnosed with COPD for at least 1 year;Post-bronchodilator spirometry at screening must demonstrate FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal;
- For patients: mMRC Scoring at screening ≥2;
- For patients: Clinically stable COPD in the previous 4 weeks;
- For patients: Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication;
- For patients: Current and former smokers with a smoking history of ≥10 pack years(smoking at least 20 cigarettes a day for 10 years or at least 10 cigarettes a day for 20 years);
- For patients: beta agonists are currently used only "when needed";
- For patients: Never smoked or An ex-smoker for ≥6 months;
Exclusion Criteria:
- Preexisting or existing the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, immune system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator assesses that may affect drug metabolism or safety.
- For healthy subjects: Have a history of fainting needles, fainting blood.
- For healthy subjects: Known allergy to the study drug and their metabolites or any of the excipients of the formulation.
- For healthy subjects: Those who smoked more than 5 cigarettes per day during the 3 months before the trial.
- A history of alcohol abuse in the past 6 months (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).
- For healthy subjects: Donated blood or had substantial loss of blood (more than 400 mL) within 2 months before the test.
- For healthy subjects: Had taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug.
- Participated in other clinical trials within 3 months prior to this study.
- Positive for hepatitis (including hepatitis B and C), human immunodeficiency virus(HIV) or syphilis at screening.
- Women who are pregnant or breast-feeding.
- Positive test for alcohol.
- For healthy subjects: Blood collection is difficult or cannot tolerate venipuncture blood collection.
- For healthy subjects: The subject is unable or can not comply with ward management regulations.
- For healthy subjects: The subject is unable to complete the study due to personal reasons.
- For healthy subjects: Any circumstances that the investigator considers to pose a safety risk to the subject during the study or may interfere with the conduct of the study.
- For patients: Intolerance to salbutamol, tiotropium, or this product or prior exposure to Ensifentrine (RPL554).
- For patients: Use of any medicine within 4 weeks prior to initiation of the study drug, including non-prescription medications and herbs, except vitamins.
- For patients: Physical examination findings that researchers consider clinically significant at the time of screening.
- For patients: A history of cardiovascular disease (including arrhythmias) or active hyperthyroidism.
- For patients: History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TQC3721 suspension for inhalation
Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0
mg/24.0
mg single dose of TQC3721 suspension for inhalation on Day 1.
|
Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0
mg/24.0
mg single dose of TQC3721 suspension for inhalation.
|
PLACEBO_COMPARATOR: TQC3721 suspension placebo for inhalation
Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation on Day 1.
|
Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: From the enrollment of the subjects to 72 hours after the last administration
|
The Number of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
From the enrollment of the subjects to 72 hours after the last administration
|
Incidence of adverse events
Time Frame: From the enrollment of the subjects to 72 hours after the last administration
|
The Incidence of adverse events as assessed by CTCAE v5.0
|
From the enrollment of the subjects to 72 hours after the last administration
|
Number of adverse events related to the study drug
Time Frame: From the enrollment of the subjects to 72 hours after the last administration
|
The number of adverse events associated with the study drug assessed by CTCAE V5.0
|
From the enrollment of the subjects to 72 hours after the last administration
|
Incidence of adverse events associated with the study drug
Time Frame: From the enrollment of the subjects to 72 hours after the last administration
|
Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0
|
From the enrollment of the subjects to 72 hours after the last administration
|
Area Under The Curve(AUC)
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Area under the curve
|
Within 60 minutes before each administration, to 72 hours after administration
|
Plasma drug peak concentration(Cmax )
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Plasma drug peak concentration
|
Within 60 minutes before each administration, to 72 hours after administration
|
Time to peak(Tmax)
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Time to maximum concentration following drug administration
|
Within 60 minutes before each administration, to 72 hours after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Elimination half-life time(t1/2)
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Apparent terminal elimination half-life following drug administration
|
Within 60 minutes before each administration, to 72 hours after administration
|
Apparent volume of distribution(Vd)
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Apparent volume of distribution
|
Within 60 minutes before each administration, to 72 hours after administration
|
Clearance(CL)
Time Frame: Within 60 minutes before each administration, to 72 hours after administration
|
Clearance
|
Within 60 minutes before each administration, to 72 hours after administration
|
Forced Expiratory Volume in the first second (FEV1) for patients with Chronic Obstructive Pulmonary Disease(COPD) or asthma
Time Frame: From before administration to 3 hours after administration
|
Mean Change From Baseline in Peak FEV1 (Over 3 Hours)
|
From before administration to 3 hours after administration
|
Mean Change From Baseline FEV1 to Morning Trough FEV1
Time Frame: From the enrollment of the subjects to to 72 hours after administration
|
Mean Change From Baseline FEV1 to Morning Trough FEV1
|
From the enrollment of the subjects to to 72 hours after administration
|
Mean Change From Baseline FEV1 to Average FEV1
Time Frame: From the enrollment of the subjects to to 72 hours after administration
|
Mean Change From Baseline FEV1 to Average FEV1
|
From the enrollment of the subjects to to 72 hours after administration
|
COPD Assessment Test (CAT) for patients with COPD
Time Frame: From enrollment to 4 weeks after administration
|
Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week 4.The score range is 0 to 40 (0 to 10 is minor influence;11 to 20 is moderate; 21 to30 is severe;31 to 40 is very severe), and more than 10 indicates more symptoms.
|
From enrollment to 4 weeks after administration
|
Modified medical research council(mMRC) for patients with COPD or asthma
Time Frame: From enrollment to 4 weeks after administration
|
Mean Change From Baseline in mMRC Scoring at Week 4.The severity is measured on a five-point scale from 0 to 4, with a higher score indicating more severe respiratory distress.
|
From enrollment to 4 weeks after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 18, 2021
Primary Completion (ANTICIPATED)
October 31, 2022
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
August 17, 2021
First Submitted That Met QC Criteria
September 12, 2021
First Posted (ACTUAL)
September 21, 2021
Study Record Updates
Last Update Posted (ACTUAL)
October 25, 2021
Last Update Submitted That Met QC Criteria
October 22, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQC3721-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on TQC3721 suspension for inhalation
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Obstructive Pulmonary Disease (COPD)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Obstructive Pulmonary DiseaseChina
-
AstraZenecaCompletedAsthma | Chronic Obstructive Pulmonary Disease COPDUnited States
-
Insmed IncorporatedCompleted
-
Insmed IncorporatedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedMycobacterium Infections, NontuberculousUnited States, Canada
-
Insmed IncorporatedCompletedMycobacterium Infections, Nontuberculous
-
Frontier Biotechnologies Inc.Completed
-
Vigonvita Life SciencesCompleted
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionsChina
-
Liquidia Technologies, Inc.PPDRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension Due to Lung DiseasesUnited States